ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: knee

Diagnosing & Treating Hemophagocytic Lymphohistiocytosis in Adults

Srujana Pachigolla, MD, & Adegbenga Bankole, MD  |  June 15, 2020

Primary hemophagocytic lymphohistiocytosis (HLH) is caused by genetic mutations and inherited syndromes; it therefore occurs in the pediatric age group. Secondary HLH, however, is more common in adults and is often triggered by other disease states, such as malignancies, chronic immuno­suppression, infections and autoimmune disease.1,2 Macrophage activation syndrome (MAS) is a subset of secondary HLH…

Filed under:ConditionsVasculitis Tagged with:case reporthemophagocytic lymphohistiocytosishemophagocytic lymphohistiocytosis (HLH)HLHmacrophage activation syndrome

Novel Cathepsin K Inhibitor Promising for OA

Lara C. Pullen, PhD  |  June 10, 2020

Research into the disease-modifying effects of the novel cathepsin K inhibitor MIV-711 suggests it may be effective as a knee OA treatment. In OA patients using the treatment, the study documented statistically significant reductions in bone and cartilage progression…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:cathepsin-K inhibitorKnee Osteoarthritis (OA)OsteoarthritisPain

Fellowship Training Goes Virtual: COVID-19 Pandemic Creates Training Challenges

Catherine Kolonko  |  May 18, 2020

With telemedicine platforms and Zoom calls, technology is playing a large role in how rheumatology fellows are seeing patients and participating in lectures and conferences…

Filed under:Education & Training Tagged with:coronavirusCOVID-19EducationFellowsFellows-in-Trainingfellowshiptelemedicine

Andrey_Popov / shutterstock.com

How Ageism Hurts Physicians & Patients

Steven M. Harris, Esq.  |  May 15, 2020

Ageism is defined as stereo­typing, prejudice or discrimination against individuals on the basis of their age. According to the American Medical Association (AMA), 43% of all physicians and surgeons are 55 or older. Specialists are, on average, older than primary care doctors. In addition, around 30% of the current U.S. population is older than 55,…

Filed under:EthicsLegal Updates Tagged with:ageism

Andrey_Popov / shutterstock.com

Rheumatology & Digital Wearables: What’s on the Horizon?

Carina Stanton  |  May 15, 2020

SNOWMASS VILLAGE, COLO.—A major workforce shortage, a population of patients taking immunosuppressants where safety concerns and the patient experience are critical, and an increasing focus on remote patient monitoring and telehealth are driving a discussion regarding the role digital wearables play in rheumatologic care. “We need to be more thoughtful and efficient in taking care…

Filed under:AppsTechnologyWorkforce Tagged with:digital wearablespatient datatelehealthWinter Rheumatology Summitworkforce shortage

Lemau Studio / shutterstock.com

Tips for Understanding the Pathways of Pain & Choosing Treatments

Carina Stanton  |  May 15, 2020

SNOWMASS VILLAGE, COLO.—The science underlying the neurobiology of chronic pain isn’t something rheumatologists often think about. However, pain is an important reason why patients see a rheumatologist. At the 2020 ACR Winter Symposium in January, Leslie Crofford, MD, gave two presentations addressing pain experienced by rheumatology patients, including a session on the fundamental mechanisms of…

Filed under:AnalgesicsConditions Tagged with:Pain Managementpain mechanismspain pathwaysWinter Rheumatology Summit

The initial physical examination was significant for a nonblanching, papular rash along the palmar aspects of the hands and digits, periungual erythema, and edema and tenderness of the proximal and distal interphalangeal joints of the hands.

Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap

Vania Lin, MD, MPH, & Leah Krull, MD  |  May 15, 2020

Clinically amyotrophic dermatomyositis (CADM), a subset of dermatomyositis (DM), is a rare autoimmune disease characterized by typical DM cutaneous findings (e.g., heliotrope rash, Gottron papules, Gottron sign) without evidence of myositis.1 The incidence of DM and CADM is approximately 9.63 per 1 million people and 2.08 per 1 million people, respectively.2 The association with development…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Clinically Amyotrophic Dermatomyositis (CADM)combination therapyinterstitial lung disease (ILD)

FDA Considers Tanezumab Application for Chronic OA Pain

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2020

The FDA is considering an application for subcutaneous tanezumab, a monoclonal antibody, as a treatment for moderate to severe osteoarthritis…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Chronic painFDAosteoarthritis (OA)PainPain ManagementtanezumabU.S. Food and Drug Administration (FDA)

Coding Corner Questions: An Office Personnel Quiz

From the College  |  April 15, 2020

A 65-year-old male patient diagnosed with rheumatoid arthritis at multiple sites without rheumatoid factor has been ordered to have infliximab infusions. What should support staff do to ensure this procedure can be given to the patient? Make sure there is a signed order from the provider Make sure a prior authorization is obtained Make sure…

Filed under:Billing/CodingConditionsFrom the CollegeOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:Osteoporosisrituximab

Case Report: A Patient’s Clubbing & Arthralgias Resist Diagnosis

Theodore Korty, DO, & Adam Grunbaum, DO  |  April 15, 2020

A 59-year-old woman presented to our rheumatology clinic with a six-month history of a symmetric polyarthritis. She initially experienced pain in both knees. As time progressed, she began to notice pain in her ankles, hips, shoulders, hands and feet. She experienced joint stiffness lasting for more than 30 minutes every morning. She also described worsening…

Filed under:Conditions Tagged with:arthralgiasCancercase reportclubbinghypertrophic osteoarthropathy (HOA)

  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 80
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences